- Home
- RNAZ vs ISPC Comparison
RNAZ vs ISPC Comparison
Compare RNAZ & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- ISPC
- Stock Information
- Founded
- RNAZ 2016
- ISPC 2009
- Country
- RNAZ United States
- ISPC United States
- Employees
- RNAZ N/A
- ISPC 24
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- RNAZ Health Care
- ISPC Health Care
- Exchange
- RNAZ Nasdaq
- ISPC Nasdaq
- Market Cap
- RNAZ 6.1M
- ISPC 13.9M
- IPO Year
- RNAZ 2021
- ISPC 2021
- Fundamental
- Price
- RNAZ $11.50
- ISPC $1.49
- Analyst Decision
- RNAZ Strong Buy
- ISPC
- Analyst Count
- RNAZ 1
- ISPC 0
- Target Price
- RNAZ $280.00
- ISPC N/A
- AVG Volume (30 Days)
- RNAZ 10.7K
- ISPC 20.3M
- Earning Date
- RNAZ 11-13-2025
- ISPC 11-06-2025
- Dividend Yield
- RNAZ N/A
- ISPC N/A
- EPS Growth
- RNAZ N/A
- ISPC N/A
- EPS
- RNAZ N/A
- ISPC N/A
- Revenue
- RNAZ N/A
- ISPC $5,908,088.00
- Revenue This Year
- RNAZ N/A
- ISPC $35.93
- Revenue Next Year
- RNAZ N/A
- ISPC N/A
- P/E Ratio
- RNAZ N/A
- ISPC N/A
- Revenue Growth
- RNAZ N/A
- ISPC N/A
- 52 Week Low
- RNAZ $6.15
- ISPC $0.64
- 52 Week High
- RNAZ $739.20
- ISPC $8.30
- Technical
- Relative Strength Index (RSI)
- RNAZ 57.47
- ISPC 55.29
- Support Level
- RNAZ $10.67
- ISPC $1.47
- Resistance Level
- RNAZ $11.76
- ISPC $2.58
- Average True Range (ATR)
- RNAZ 0.63
- ISPC 0.46
- MACD
- RNAZ 0.10
- ISPC 0.08
- Stochastic Oscillator
- RNAZ 89.47
- ISPC 33.57
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.